Literature DB >> 8812867

Purification and characterization of human tissue prokallikrein and kallikrein isoforms expressed in Chinese hamster ovary cells.

H S Lu1, Y R Hsu, L O Narhi, S Karkare, F K Lin.   

Abstract

We report here the expression of recombinant human prokallikrein and kallikrein in engineered Chinese hamster ovary cells transfected with a human genomic gene encoding preprokallikrein. At high expression levels, recombinant prokallikrein, an inactive proenzyme form, is predominantly secreted into the culture medium. Upon chromatographic separations, the inactive prokallikrein as well as the mature kallikrein after thermolysin activation of the proenzyme can be prepared to apparent purity. Both prokallikrein and kallikrein can be further separated into two distinct high- and low-molecular-weight isoforms. Kallikrein preparations are fully active in standard kallikrein activity assays such as esterase activity and kinin release from kininogen. Both kallikrein and prokallikrein display multiple molecular forms with differences in both molecular sizes and charges. The structural differences in high- and low-molecular-weight kallikreins or prokallikreins were found to be due to glycosylation, with the high-molecular-weight species glycosylated at three Asn-linked sites and the low-molecular-weight species at two of the three Asn-linked sites. The multiply charged kallikrein isoforms are derived from different numbers of sialic acids attached at the detected Asn-linked carbohydrates. In comparison with kallikrein, prokallikrein appears to show a significant decrease in the magnitude of near uv-circular dichroism bands, suggesting a change in local conformation. This conformational change correlates with the loss of activity in proenzyme due to the presence of propeptide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8812867     DOI: 10.1006/prep.1996.0095

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  4 in total

1.  A target-specific approach for the identification of tyrosine-sulfated hemostatic proteins.

Authors:  Tzu-An Liu; Shin Yasuda; Frederick E Williams; Ming-Yih Liu; Masahito Suiko; Yoichi Sakakibara; Yuh-Shyong Yang; Ming-Cheh Liu
Journal:  Anal Biochem       Date:  2009-04-05       Impact factor: 3.365

2.  Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors.

Authors:  Xavier Charest-Morin; Arvind Raghavan; Matthew L Charles; Tadeusz Kolodka; Johanne Bouthillier; Mélissa Jean; Mark S Robbins; François Marceau
Journal:  Pharmacol Res Perspect       Date:  2015-02-10

3.  Autoimmune diabetes is suppressed by treatment with recombinant human tissue Kallikrein-1.

Authors:  Lilia Maneva-Radicheva; Christina Amatya; Camille Parker; Jacob Ellefson; Ilian Radichev; Arvind Raghavan; Matthew L Charles; Mark S Williams; Mark S Robbins; Alexei Y Savinov
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

4.  Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus.

Authors:  Tadeusz Kolodka; Matthew L Charles; Arvind Raghavan; Ilian A Radichev; Christina Amatya; Jacob Ellefson; Alexei Y Savinov; Abhijeet Nag; Mark S Williams; Mark S Robbins
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.